RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

I agree with what neuro wrote about why mask-induced anxiety is not so likely to be a problem. There's another aspect: the outcome of RD-2 alerted cor to the problem, and they certainly could enquire about experiment failure rate, in light of RD-2. If the news were bad, they wouldn't wait for the analysis, since they pretty much would know the outcome based on the failure rate.

My point is that if the data were mush, they'd know already. They would have known at the time of the RD-2 results announcement.

Like everything else with cor, this isn't a binary variable: they probably have a trend to detect among those participants who didn't wash out (they could likely tolerate up to a 50% failure rate). They may have reason to believe that they have enough data for significance, so they're going ahead with the full analysis.

My hope is that they're not grasping at straws, and that their reasons for going ahead with the full analysis (and the prolonged delay) are well-founded. I think that the slow rate of progress we're seeing here is intentional. It is easy to tell people to take their time. On this view, they are slowing the process to move the announcement into September, when the news will be noticed, which, if true, reflects confidence.

I think that they will do a partnership covering all analgesia/RD indications. I think the OSA will not be part of the deal.